A Study of A4368 in Healthy Subjects

Inclusion criteria

• Healthy male and female subjects
• Subject with a body weight of ≥ 55.0 kg and within an ideal body weight ± 20%
• Consent to follow the contraceptive guidance during the treatment period and for at least 3 months after the last dose of study drug
• Willing and able to sign the informed consent form

Exclusion criteria

• History of or current clinically significant medical illness
• History of or current gastrointestinal disease or surgery that can influence in pharmacokinetics of study drug
• Clinically significant history of hypersensitivity to study drug or any of the excipients of study drug
• Pregnant or lactating woman
• Clinically significant abnormal laboratory values for hematology, clinical chemistry, or urinalysis
• Clinically significant abnormal physical examination, vital signs, or 12-lead ECG
• Heavy alcohol or caffeine intake or heavy smoker
• Use of study drug in concurrent interventional study within 180 days prior to the first dose of study drug
• Use of any drug that may affect drug metabolic enzymes within 30 days prior to the first dose of study drug
• Donation of whole blood within 60 days or apheresis within 30 days prior to the first dose of study drug
• Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days prior to the first dose of study drug